Neovacs S.A. (ALNEV) — Capital Reinvestment Ratio

Latest as of December 2023: 0.10x

Neovacs S.A. (ALNEV) has a Capital Reinvestment Ratio of 0.10x as of December 2023, meaning it reinvests 0% of its operating cash flow (€1.47 Million) in capital expenditures (€150.45K). See Neovacs S.A. balance sheet independence to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.10x

Capex / Operating Cash Flow

Operating Cash Flow

€1.47 Million

EUR

Capital Expenditures

€150.45K

EUR

Data as of

Dec 2023

Most recent filing

Annual Capital Reinvestment Ratio for Neovacs S.A. (None–None)

Year-by-year Capital Reinvestment Ratio for Neovacs S.A. from None to None. For live market cap and broader valuation context, see Neovacs S.A. market capitalisation.

Year	Reinvestment Ratio	Operating CF (EUR)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow